<?xml version="1.0" encoding="utf-8" ?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving
and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">

<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.2" article-type="other">

<front>


<article-meta>


<title-group>
<article-title>Recommendations for reporting epidemiological
parameters</article-title>
</title-group>

<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">0000-0001-5218-3046</contrib-id>
<name>
<surname>Lambert</surname>
<given-names>Joshua W.</given-names>
</name>
<string-name>Joshua W. Lambert</string-name>

<email>joshua.lambert@lshtm.ac.uk</email>
<xref ref-type="aff" rid="aff-1">a</xref>
<xref ref-type="corresp" rid="cor-1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0003-4184-2864</contrib-id>
<name>
<surname>Tamayo</surname>
<given-names>Carmen</given-names>
</name>
<string-name>Carmen Tamayo</string-name>

<email>carmen.tamayo-cuartero@lshtm.ac.uk</email>
<xref ref-type="aff" rid="aff-1">a</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0001-6525-101X</contrib-id>
<name>
<surname>Bhatia</surname>
<given-names>Sangeeta</given-names>
</name>
<string-name>Sangeeta Bhatia</string-name>

<email>s.bhatia@imperial.ac.uk</email>
<xref ref-type="aff" rid="aff-2">b</xref>
<xref ref-type="aff" rid="aff-3">c</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-6368-9103</contrib-id>
<name>
<surname>McCabe</surname>
<given-names>Ruth</given-names>
</name>
<string-name>Ruth McCabe</string-name>

<email>ruth.mccabe17@imperial.ac.uk</email>
<xref ref-type="aff" rid="aff-2">b</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0001-6821-0352</contrib-id>
<name>
<surname>Cuomo-Dannenburg</surname>
<given-names>Gina</given-names>
</name>
<string-name>Gina Cuomo-Dannenburg</string-name>

<email>g.cuomo-dannenburg18@imperial.ac.uk</email>
<xref ref-type="aff" rid="aff-2">b</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0001-8814-9421</contrib-id>
<name>
<surname>Kucharski</surname>
<given-names>Adam</given-names>
</name>
<string-name>Adam Kucharski</string-name>

<email>adam.kucharski@lshtm.ac.uk</email>
<xref ref-type="aff" rid="aff-1">a</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-8443-9162</contrib-id>
<name>
<surname>Cori</surname>
<given-names>Anne</given-names>
</name>
<string-name>Anne Cori</string-name>

<email>a.cori@imperial.ac.uk</email>
<xref ref-type="aff" rid="aff-2">b</xref>
</contrib>
</contrib-group>
<aff id="aff-1">
<institution-wrap>
<institution>London School of Hygiene and Tropical
Medicine</institution>
</institution-wrap>







</aff>
<aff id="aff-2">
<institution-wrap>
<institution>Imperial College London</institution>
</institution-wrap>







</aff>
<aff id="aff-3">
<institution-wrap>
<institution>UK Health Security Agency</institution>
</institution-wrap>







</aff>
<author-notes>
<corresp id="cor-1">joshua.lambert@lshtm.ac.uk</corresp>
</author-notes>









<history></history>


<kwd-group kwd-group-type="author">
<kwd>epidemiological parameters</kwd>
<kwd>reporting guidelines</kwd>
</kwd-group>




</article-meta>

</front>

<body>
<p>Epidemiological parameters are a necessity in understanding the
spread of infectious disease; from the rate of transmission, to
severity, to serology, these parameters underline our ability to
quantify and respond to disease outbreaks. The estimation of
epidemiological parameters has a long history in epidemiology and the
models and methods applied have become more complex; and with this
complexity comes the numerous ways parameters can be reported in the
literature. Here we provide guidance on how to clearly communicate
estimated epidemiological parameters, to maximise their secondary use
and minimise possible human errors that come with extracting parameters
from the literature and applying them in their own epidemiological
analysis. Our aim is for future work that reports epidemiological
parameters to be consistent, reproducible and comparable.</p>
<sec id="introduction">
  <title>Introduction</title>
  <p>Epidemiological parameters are quantities that characterise the
  spread of infectious diseases, their epidemiological outcomes and
  temporal information on dynamics of disease progression and
  transmission
  (<xref alt="Cori and Kucharski 2024" rid="ref-coriInferenceEpidemicDynamics2024" ref-type="bibr">Cori
  and Kucharski 2024</xref>). They are critical to understand epidemic
  and pandemic dynamics and respond accordingly
  (<xref alt="Polonsky et al. 2019" rid="ref-polonskyOutbreakAnalyticsDeveloping2019" ref-type="bibr">Polonsky
  et al. 2019</xref>). Most epidemiological parameters take the form of
  distributions because there is inherent variability in the
  epidemiological characteristics being measured. An illustration is the
  delay from infection to symptom onset. The variability of individuals
  in immune response and variability of the infectious agent in
  pathology are two ways, among many others, that lead to some
  individuals having shorter time delay between infection and onset of
  symptoms. Due to most epidemiological parameters being described by
  distributional forms they are estimated by fitting distributions to
  epidemiological data on cases or contacts.</p>
  <p>It has become general practice that when epidemiological parameters
  are required, either for analyses of epidemiological case data or to
  make policy decisions like quarantine duration, that the literature is
  searched to find a suitable peer-reviewed publication reporting the
  parameter needed. However, this process has several limitations. The
  time requirement to search through papers to find the highest quality
  epidemiological parameter means that in time-limited scenarios, for
  example early in an outbreak when the situation is evolving rapidly
  and new data is continually gathered, a suboptimal parameter set may
  be extracted and used. This has lead to previous <italic>ad
  hoc</italic> reviews of epidemiological parameters for specific
  pathogens (e.g. Ebola
  (<xref alt="Van Kerkhove et al. 2015" rid="ref-vankerkhoveReviewEpidemiologicalParameters2015a" ref-type="bibr">Van
  Kerkhove et al. 2015</xref>)). The choice of parameter is also likely
  to be somewhat subjective without a clear quality assurance framework
  to evaluate and compare different parameter estimates. The manual
  extraction of copying and pasting parameters out of the literature
  comes with the risk of discrepancies entering the calculations.</p>
  <p>Epidemiological parameters have been reported for many diseases and
  the data used to infer parameter estimates and the methods of
  inference vary.</p>
  <p>Efforts to compile a centralised database of epidemiological
  parameters have highlighted the variability and ambiguity in parameter
  reporting which can lead to uncertainty around what is being reported
  and how these epidemiological parameters can be applied in other
  epidemiological analyses
  (<xref alt="Cuomo-Dannenburg et al. 2024" rid="ref-cuomo-dannenburgMarburgVirusDisease2024" ref-type="bibr">Cuomo-Dannenburg
  et al. 2024</xref>;
  <xref alt="Doohan et al. 2024" rid="ref-doohanLassaFeverOutbreaks2024" ref-type="bibr">Doohan
  et al. 2024</xref>;
  <xref alt="Nash et al. 2024" rid="ref-nashEbolaVirusDisease2024" ref-type="bibr">Nash
  et al. 2024</xref>).</p>
  <p>This paper was motivated by several research groups independently
  attempting to compile a comprehensive library of epidemiological
  parameters which could serve as a public resource to easily search,
  filter and extract parameters. These groups gathered for a workshop
  convened by the World Health Organisation (WHO) Collaboratory in
  Spring 2024, in which a Global Repository of Epidemiological
  Parameters (GREP) was discussed, as well as ideas for guidance on
  reporting epidemiological parameters. The guidelines and examples of
  incorrect reporting and use were subsequently further developed and
  resulted in this paper.</p>
  <p>Our focus is on guidance for reporting epidemiological parameters
  from a variety of study types and estimation methodologies. We do not
  cover or advice on best practises for parameter estimation methods.
  There are several papers that address avoiding biases and pitfalls
  [(<xref alt="kingAvoidableErrorsModelling2015?" rid="ref-kingAvoidableErrorsModelling2015" ref-type="bibr"><bold>kingAvoidableErrorsModelling2015?</bold></xref>);
  brittonEstimationEmergingEpidemics2019a]. Specificall for guidance on
  methodologies when inferring delay distributions see Park et al.
  (<xref alt="2024" rid="ref-parkEstimatingEpidemiologicalDelay2024" ref-type="bibr">2024</xref>)
  and Charniga et al.
  (<xref alt="2024" rid="ref-charnigaBestPracticesEstimating2024" ref-type="bibr">2024</xref>),
  and when inferring the reproduction number see
  (<xref alt="gosticPracticalConsiderationsMeasuring2020a?" rid="ref-gosticPracticalConsiderationsMeasuring2020a" ref-type="bibr"><bold>gosticPracticalConsiderationsMeasuring2020a?</bold></xref>)
  and abbottEstimatingTimevaryingReproduction2020. We focus on the
  reporting of epidemiological parameters post-inference and the
  benefits of reporting standardisation on the reuse of parameters by
  those involved in epidemic or humanitarian response.</p>
  <p>We classify bad parameter reporting into two groups: 1)
  <italic>information loss</italic> and 2) <italic>ambiguous
  reporting</italic>. Information loss is defined as the presentation or
  sharing of less than the entirety of the parameter estimates, metadata
  and contextual information. For example, if a method to infer a case
  fatality rate outputs the uncertainty of the risk but this is not
  reported either in the text and the method cannot be reproduced then
  this information is lost when others extract the parameters, i.e. only
  a subset of the full inference is shared. Ambiguous reporting can be
  either the ambiguous reporting of metrics, such as a
  <inline-formula><alternatives>
  <tex-math><![CDATA[X \pm Y]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>X</mml:mi><mml:mo>±</mml:mo><mml:mi>Y</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>
  where <inline-formula><alternatives>
  <tex-math><![CDATA[Y]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Y</mml:mi></mml:math></alternatives></inline-formula>
  could be the standard deviation or standard error, or
  <inline-formula><alternatives>
  <tex-math><![CDATA[X (Y_1 - Y_2)]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>X</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
  where the bounds <inline-formula><alternatives>
  <tex-math><![CDATA[Y_1]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>Y</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math></alternatives></inline-formula>
  and <inline-formula><alternatives>
  <tex-math><![CDATA[Y_2]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>Y</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math></alternatives></inline-formula>
  could be a confidence interval or credible interval when the inference
  framework is not reported. In both cases the secondary use of the
  parameters either is forced to make an assumption on what is reported,
  or does not utilise the information resulting in information loss.</p>
  <p>Here we focus on the bias caused by badly reported epidemiological
  parameters on simple epidemic methods, sometimes referred to as
  outbreak analytics (sensu
  <xref alt="Polonsky et al. 2019" rid="ref-polonskyOutbreakAnalyticsDeveloping2019" ref-type="bibr">Polonsky
  et al. 2019</xref>), to showcase the erroneous conclusions that can
  arise when using parameter estimates from the literature. The biases
  produce here will likely extrapolate to more complex
  epidemiologilogical modelling. Reporting guidelines can ensure
  standardised reporting becomes more commonplace, which can make it
  easier to review, summarise and aggregate epidemiological parameters.
  We hope that this paper, alongside other works on reporting best
  practises in epidemiology
  (<xref alt="pollettRecommendedReportingItems2021?" rid="ref-pollettRecommendedReportingItems2021" ref-type="bibr"><bold>pollettRecommendedReportingItems2021?</bold></xref>;
  <xref alt="Charniga et al. 2024" rid="ref-charnigaBestPracticesEstimating2024" ref-type="bibr">Charniga
  et al. 2024</xref>) enhance the interoperability of research outputs
  and inputs.</p>
</sec>
<sec id="guidance">
  <title>Guidance</title>
  <sec id="parameter-inference-reporting">
    <title>Parameter inference reporting</title>
    <sec id="parameterisation-of-distributions">
      <title>Parameterisation of distributions</title>
      <p>Many distributions have standard parameterisations. In other
      words, they have one, two or in some cases three parameters that
      are denoted by a name and often have a greek letter for shorthand.
      An example of this is the Gamma distribution which has the
      parameterisation shape (<inline-formula><alternatives>
      <tex-math><![CDATA[\alpha]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>)
      and rate (<inline-formula><alternatives>
      <tex-math><![CDATA[\beta]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>).
      However, there are often alternative parameterisations, for the
      Gamma distribution this is shape (<inline-formula><alternatives>
      <tex-math><![CDATA[k]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>k</mml:mi></mml:math></alternatives></inline-formula>)
      and scale (<inline-formula><alternatives>
      <tex-math><![CDATA[\theta]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>θ</mml:mi></mml:math></alternatives></inline-formula>).
      If left unspecified, the reported parameters may correspond to
      different parameters depending on interpretation. Another example
      of ambiguous reporting of distribution estimates is when the
      parameters and summary statistics have similar names. This is the
      case for the lognormal distribution, whose common parameterisation
      is meanlog (<inline-formula><alternatives>
      <tex-math><![CDATA[\mu]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>)
      and sdlog (<inline-formula><alternatives>
      <tex-math><![CDATA[\sigma]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>σ</mml:mi></mml:math></alternatives></inline-formula>)
      and common summary statistics reported for a distribution are mean
      and standard deviation (sd), this is further confused as both use
      the same greek letters. Therefore, it is possible to mistake the
      reporting of one set of these for the other. Both types of
      misinterpretation outlined here can result in substantial
      differences in the distributions (Figure 1).</p>
      <boxed-text>
      <p><bold><italic>Guidance</italic></bold></p>
      <list list-type="bullet">
        <list-item>
          <p>Provide the formula for the Probability Density Function
          (PDF), or Probability Mass Function (PMF) if discrete, in the
          text or supplementary material.</p>
        </list-item>
        <list-item>
          <p>Clearly report which distribution parameterisation was used
          to estimate parameters and provide parameter names in the
          text.</p>
        </list-item>
        <list-item>
          <p>Share code used to estimate parameter(s) for others to
          reproduce and audit methods.</p>
        </list-item>
      </list>
      </boxed-text>
      <fig id="fig-dist-params">
        <caption><p>Figure 1</p></caption>
        <fig id="fig-dist-params-1">
          <caption><p>(a) Differences in distributions when
          misinterpreting the estimated parameters. (a) Two gamma
          distributions, the blue shows a gamma distribution with shape
          (<inline-formula><alternatives>
          <tex-math><![CDATA[\alpha]]></tex-math>
          <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>)
          and rate (<inline-formula><alternatives>
          <tex-math><![CDATA[\beta]]></tex-math>
          <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>)
          of 2, the red shows a gamma distribution with shape
          (<inline-formula><alternatives>
          <tex-math><![CDATA[k]]></tex-math>
          <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>k</mml:mi></mml:math></alternatives></inline-formula>)
          and scale (<inline-formula><alternatives>
          <tex-math><![CDATA[\theta]]></tex-math>
          <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>θ</mml:mi></mml:math></alternatives></inline-formula>)
          of 2. The rate is the reciprocal of the scale
          (<inline-formula><alternatives>
          <tex-math><![CDATA[\beta]]></tex-math>
          <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>
          = 1/<inline-formula><alternatives>
          <tex-math><![CDATA[\theta]]></tex-math>
          <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>θ</mml:mi></mml:math></alternatives></inline-formula>),
          but it is clear from the left hand plot that misinterpreting
          the parameter leads to a vastly different distribution
          density. (b) Two lognormal distributions, the orange shows the
          density of a lognormal distribution with meanlog
          (<inline-formula><alternatives>
          <tex-math><![CDATA[\mu]]></tex-math>
          <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>)
          and sdlog (<inline-formula><alternatives>
          <tex-math><![CDATA[\sigma]]></tex-math>
          <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>σ</mml:mi></mml:math></alternatives></inline-formula>)
          of 0.5, and the green with the meanlog and sdlog of 1.87 and
          1.00, respectively (these values are the conversion from
          meanlog and sdlog into mean and standard deviation). Again
          showing how misinterpreting the parameters can lead to
          differences in epidemiological parameters.</p></caption>
          <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/use_cases-dist_params-fig-dist-params-output-1.png" />
        </fig>
        <fig id="fig-dist-params-2">
          <caption><p>(b)</p></caption>
          <graphic id="fig-dist-params-2" mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/use_cases-dist_params-fig-dist-params-output-2.png" />
        </fig>
      </fig>
    </sec>
    <sec id="parameter-estimates-vs-summary-statistics">
      <title>Parameter estimates vs summary statistics</title>
      <p>Instead of reporting the parameter estimates for a parametric
      distribution, summary statistics may be provided. In some
      instances a set of summary statistics can be analytically
      converted into distribution parameters (the specific summary
      statistics that can be converted into parameters varies by
      distribution). In those cases where analytical conversion can be
      done there is no loss in parameter estimate precision,
      i.e. summary statistics are sufficient statistics. Commonly
      reported sufficient statistics are the mean and standard deviation
      or variance of a distribution. However, it can also be the case
      that summary statistics that cannot be analytically converted to
      distribution parameters are reported, for example the mean or
      median and the 95th percentiles of the distribution. In these
      cases, distribution parameters require a second estimation using a
      numerical conversion. Numerical conversion can introduce more
      uncertainty and potentially return erroneous estimates. Below we
      show an example of the bias and variance of distribution
      parameters when numerically converted from summary statistics…
      (see {epiparameter} R package article for full exploration of bias
      in numerical conversion).</p>
      <boxed-text>
      <p><bold>Use case: Incubation period</bold></p>
      <p><bold>Example use case: estimating the upper quantile of the
      incubation period distribution</bold></p>
      <p>The incubation period, defined as the time between infection
      and the development of symptoms, is an important epidemiological
      quantity for establishing guidance on the duration of contact
      tracing of identified cases, as well as the duration of isolation
      or quarantine for subsequently identified contacts. It is critical
      that the duration of isolation mitigates the risk of onward
      transmission, but does not extend any longer than necessary due to
      the costs, both financial and social, associated with isolation.
      The incubation period is most typically presented as a probability
      distribution, but is often summarised by a mean and estimate of
      the variability (most commonly standard deviation), rather than
      the full distribution.
      Consider the following example. During a novel Ebola outbreak, the
      incubation period is estimated using a gamma distribution on just
      a small number of observations (due to the lack of testing and
      contact tracing). MCMC methods are used to obtain 100 realisations
      of a gamma distribution:</p>
      <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/unnamed-chunk-5-1.png" />
      <p>This analysis has been repeated several times for this paper,
      corresponding to different locations and time periods. For sake of
      space and simplicity, the results per fit are presented in the
      typical fashion, as noted above:
      Mean: 12.86 (95% CI 8.67 - 17.99)
      SD: 13.11 (95% CI 8.75 - 18.43)
      However, this omits critical information about the upper 95%
      quantile of the distribution, which from the figure, is highly
      variable across realisations. Specifically, this is estimated as:
      95% quantile: 38.9 (95% CI 28.7 - 51.8)
      which has substantial uncertainty.
      In a future outbreak of a viral hemorrhagic fever, the public
      health authority in the affected country looks to the previous
      analysis to guide their quarantine policy. Using only the provided
      information (the mean and SD), it is possible to use method of
      moments for the gamma distribution to obtain estimates of the
      shape and scale parameters (0.93 and 13.62, respectively).
      Parameterising a gamma distribution according to these parameters
      corresponds to a 95% quantile of 39 days. This recovers the
      central estimate above well. However, it is not possible to obtain
      any uncertainty around this estimate without the authors having
      provided the full set of samples used to generate these estimates.
      This may provide a false sense of certainty on which the
      quarantine policy is based, whereas there may be an argument to
      either extend or reduce this based on the considerable uncertainty
      estimated above.</p>
      </boxed-text>
      <p>Epidemiological parameters can be dimensionless quantities, for
      example R0 or secondary attack rate, while others have units. It
      is especially critical for the accurate reuse of with dimensions
      parameters that the units are reported. For parameters with a
      temporal dimension, such as delay distributions, the unit of time
      ensures that distributions fitted to data on days or weeks can be
      clearly understood. Another example is viral load data that can be
      reported as Ct or log10 RNA copies/ml. Many epidemiological
      parameters will have conventional units, for example incubation
      period and serial interval in days, or population density in
      individuals/km, but if readers have to assume units then
      misinterpretation can have consequences for others that apply the
      findings in their own work.</p>
      <p><italic>Guidance</italic>:</p>
      <list list-type="bullet">
        <list-item>
          <p>Report the estimated distribution parameters first and
          foremost before optionally reporting summary statistics. This
          will avoid any secondary estimation step which can introduce
          unwanted and unnecessary bias.</p>
        </list-item>
        <list-item>
          <p>If a parameter has a unit, report this with the estimates,
          ensuring it matches the data of input of the model.</p>
        </list-item>
      </list>
      <boxed-text>
      <p><bold>Use case: Severity</bold></p>
      <p><bold>Use case: Ambiguous reporting of onset-to-death delay
      distribution and erroneous CFR estimates</bold></p>
      <p>In a scenario in which the case fatality risk (CFR) needs to be
      calculated for an ongoing, growing disease outbreak an
      onset-to-death delay distribution is required to calculate an
      unbiased CFR estimate, due to some individuals being infected but
      theiry outcome (i.e recovery or death) is unknown Nishiura et al.
      (<xref alt="2009" rid="ref-nishiuraEarlyEpidemiologicalAssessment2009" ref-type="bibr">2009</xref>).</p>
      <p>A line list of the current outbreak is available, but no
      estiates of the onset-to-death delay are available for this
      outbreak and there is not enough case data to reliably estimate it
      from the line list. Therefore a previously inferred onset-to-death
      distribution is searched and extracted from the literature for the
      same pathogen from a past outbreak.</p>
      <p>The paper reporting the onset-to-death states:</p>
      <disp-quote>
        <p>“… the average duration between the time when symptoms first
        appeared and death of the patients was estimated. The mean
        onset-to-death delay was of 14.5 days, with a standard deviation
        of 6.7.”</p>
      </disp-quote>
      <p>The ambiguous reporting of the esimates means the
      onset-to-death delay can be (mis)interpreted in several ways. The
      paper is reporting the summary statistics mean and standard
      deviation for a lognormal distribution they fitted to the data.
      The estimates could be misinterpreted as meanlog and sdlog do the
      lognormal distribution, or could be misinterpreted as the summary
      statistics of the raw data (i.e. sample statistics). The CFR
      calculation for an unbiased estimate requires a parametric
      probability density/mass function. Therefore, given the ambiguity
      we demonstrate the correct interpretation and three
      misinterpretations of the reported onset-to-death and show how the
      CFR varies as a result. We use the {simulist} and {cfr} R packages
      to simulate line list data and calculate the CFR, respectively
      Lambert and Tamayo
      (<xref alt="2024" rid="ref-lambertSimulistSimulateDisease2024" ref-type="bibr">2024</xref>)
      and Gupte, Kucharski, and Russell
      (<xref alt="2024" rid="ref-gupteCfrEstimateDisease2024" ref-type="bibr">2024</xref>).</p>
      <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/unnamed-chunk-8-1.png" />
      <p>The correct interpretation can analytically convert the mean
      and standard deviation to the lognormal distribution parameters
      (<inline-formula><alternatives>
      <tex-math><![CDATA[\mu]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>
      = 2.86, <inline-formula><alternatives>
      <tex-math><![CDATA[\sigma]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>σ</mml:mi></mml:math></alternatives></inline-formula>
      = 0.53) and parameterise the onset-to-death, resulting in a CFR of
      0.3042, or 30.42%. Misinterpreting the estimates to be the
      lognormal parameters results in an overestimated CFR of NA.
      Assuming that the reported estimates are sample summary
      statistics, the distribution can be assumed, here we test the
      assumption that it is a lognormal (correct assumption) and a gamma
      distribution (incorrect assumption). The assumed parametric
      distribution form can be used to simulate a sample and the same
      distribution can be fit to that sample to estimate the parameters.
      In the case of assuming a lognormal distribution the CFR is
      estimated as 0.2681, whereas assuming a gamma distribution results
      in a CFR of 0.2426. The estimated CFR is biased in both cases but
      more so when the distribution is assumed incorrectly.</p>
      </boxed-text>
    </sec>
    <sec id="parameter-uncertainty-vs-sample-variability">
      <title>Parameter uncertainty vs sample variability</title>
      <p>The reporting of distributions is to encapsulate the
      variability of epidemiological delays, transmission, severity and
      others. However, there is also uncertainty around the parameters
      estimated. If it is not clearly stated that a distribution was fit
      to the data, it can be unclear whether the uncertainty around the
      mean corresponds to variation in the epidemiological case data,
      i.e. differences between individuals resulting in a distribution,
      or to the confidence or credible interval around the estimated
      mean.</p>
      <boxed-text>
      <p><bold>Use case: Sample variability versus
      uncertainty</bold></p>
      <p>Issue: A measure of uncertainty is provided, but it is not
      clear whether this uncertainty is due to sample variability, or is
      an uncertainty around the estimator.</p>
      <p>Implication: Erronoeus attribution of uncertainty to sample
      variability or vice versa can bias the downstream analysis. This
      is particularly true when the underlying data are not shared.</p>
      <p>Illustration: We illustrate this issue using simulated data
      from a gamma distribution D. We first simulate some data, get the
      observed mean and sd, and the uncertainty around these estimates.
      We then compare the observed data with that simulated with the
      erroneous interpretation of the uncertainty.</p>
      <graphic mimetype="image" mime-subtype="png" xlink:href="index_files/figure-jats/unnamed-chunk-13-1.png" />
      </boxed-text>
    </sec>
    <sec id="reporting-inference-method">
      <title>Reporting inference method</title>
      <p>The inference method used to infer epidemiological parameters
      and the uncertainty that is coupled with those estimates is also
      important to report precisely for it to be used in downstream
      analyses. One common distinction that can be made between
      inference method is whether it uses Maximum likelihood estimation
      (MLE) or Bayesian estimation. The resulting uncertainty of
      parameters, confidence intervals (CI) for MLE and credible
      intervals (CrI) for Bayesian fitting, cannot be interpreted or
      applied interchangeably
      (<xref alt="moreyFallacyPlacingConfidence2016?" rid="ref-moreyFallacyPlacingConfidence2016" ref-type="bibr"><bold>moreyFallacyPlacingConfidence2016?</bold></xref>).
      Therefore if wanting to propagate uncertainty in parameter
      estimates, incorrectly treating CI as CrI or vice versa will lead
      to bias.</p>
      <p>Reporting on Bayesian fitting also has several summary
      statistics to describe the central tendency of the inferred
      posterior sample, for example, mean, median, mode. It is
      beneficial for the specific central tendency statistic used to be
      explicitly stated.</p>
      <p><italic>Guidance</italic>:</p>
      <list list-type="bullet">
        <list-item>
          <p>Report distribution parameters with uncertainty if
          available. This can be reporting the confidence interval (CI)
          or credible interval (CrI) making it clear</p>
        </list-item>
        <list-item>
          <p>When using Bayesian inference, specifying methods used for
          posterior distribution and making posterior sample openly
          available via data sharing platform, e.g., Zenodo, Data
          Dryad.</p>
        </list-item>
      </list>
      <p>The types of distributions commonly fit to estimate delay
      distributions, such as serial interval, onset-to-event and
      incubation period, are Gamma, lognormal and Weibull. These are
      used as they are strictly positive (sometimes offsets or other
      distributions are used to account for negative serial intervals
      (Prete Jr. et al., 2021)) and are right-skewed, meaning that most
      of the distribution mass (i.e. area under the curve) is the left
      of the mean (Figure 1). It is best practice to fit multiple
      distributions to the data and compare models using likelihoods,
      information criteria or likelihood ratio tests. By reporting these
      comparisons with each set of estimated parameters it allows others
      to use the distribution they choose while also being aware of the
      goodness-of-fit if choosing the non-best-fitting distribution.</p>
      <p><italic>Guidance</italic>:</p>
      <list list-type="bullet">
        <list-item>
          <p>If multiple distributions are fit to the raw case data,
          report the goodness-of-fit (e.g. maximum likelihood, Akaike
          Information Criterion) and the parameter estimates of each
          distribution either in the main text or in the supplementary
          material.</p>
        </list-item>
      </list>
    </sec>
  </sec>
  <sec id="contextual-information-and-metadata">
    <title>Contextual information and metadata</title>
    <p>Since pathogen transmission and spread is known to be affected by
    socioeconomic, demographic, and climatic factors, reporting relevant
    contextual information alongside parameter estimates is crucial to
    understand the circumstances in which these estimates were obtained.
    Doing so will allow external readers to make informed decisions
    about the generalisability of the reported parameters and usability
    in their own analyses.</p>
    <p>An important contextual element is detailed information about the
    sample population from which parameters were estimated, including
    factors such as the geographic location, age distribution, and
    comorbidities. This is particularly relevant in those studies where
    only a specific subset of the population was sampled, such as
    health-care workers, pregnant individuals, or immunocompromised
    patients.</p>
    <p>Other relevant details of the study, such as the type of design
    and sampling strategy, should not be overlooked, when reporting
    epidemiological parameters, as these provide relevant contextual
    information to assess the representativeness of the data and
    validity of the statistical methods applied. For instance, methods
    for estimating parameters like the serial interval require
    considering data collection methods, as different adjustments for
    biases are needed depending on whether data on transmission pairs
    was conducted prospectively or retrospectively (see section 1.5).
    The specific case definition used to estimate parameters should also
    be reported, where possible, given the range of clinical signs that
    many diseases exhibit at different stages of infection, which can
    have an impact on the estimation of parameters like the incubation
    period or delays from onset to outcome.</p>
    <boxed-text>
    <p><bold>Use case: Seroprevalence</bold></p>
    <p><bold>Example use case: the importance of clear reporting of
    seroprevalence estimates</bold></p>
    <p>Estimates of seroprevalence provide critical insights into the
    level of susceptibility within a population, in turn informing the
    implementation of control measures, including vaccinations
    (e.g. through the critical fraction requiring vaccination to control
    spread).
    A novel coronavirus has been identified and is spreading throughout
    the population. A rapid seroprevalence study is undertaken to
    understand levels of immunity of the population. Initially, 5,000
    tests are carried out via enzyme-linked immunoabsorbsent assay
    (ELISA), of which 250 are positive. This corresponds to a
    seroprevalence estimate of 5% (95% exact binomial confidence
    intervals 4.4% - 5.6%).
    However, it is known that ELISA assays can be prone to
    cross-reactivity with other coronaviruses, which are also in
    circulation in this population. Therefore, it is decided to
    undertake neutralisation tests, which are typically more sensitive,
    to provide further confidence in the level of population-immunity.
    Due to a limited budget, only 500 tests can be re-tested with a
    neutralisation assay, and so all of the 250 positive tests and 250
    of the 4,750 negatives are selected randomly for further testing.
    Of the 500 samples sent for further testing, only 50 return as
    positive. For the neutralisation tests, in respect of the ELISA
    tests, this corresponds to a seroprevalence estimate of 10% (95%
    exact binomial confidence intervals 7.5% - 13%), which is notably
    higher than the seroprevalence obtained under ELISA only.
    However, discounting the results of the 4,500 tests incorrectly
    inflates estimated seroprevalence, implying a higher level of
    immunity in the population than that which is indicated by this
    study as a whole. Looking at the positive neutralisation tests out
    of the total tests (ELISA and neutralisation), seroprevalence is
    estimated as 1% (95% exact binomial confidence intervals 0.7% -
    1.3%), again subtantially lower than suggested when using the
    neutralisation test denominator only.
    </p>
    <p>Using the incorrect denominator could have important consequences
    for future planning and control strategies. Consider a population of
    1,000,000 people. The basic reproduction number of this novel
    coronavirus is estimated at around 4, implying a herd immunity
    threshold (HIT) of 75%.
    If it is (incorrectly) assumed that seroprevalence is 10%, this
    implies that 660,000 members of the population require immunity
    before herd immunity is reached. However, it is actually 740,000
    members of the population requiring immunity to reach this threshold
    (an additional 90,000 people) under the correctly specified
    seroprevalence estimate of 1%.
    If immunity were to be required through vaccination, then an
    additional 90,000 vaccines would be required. In the absence of a
    vaccine, e.g. if immunity were to be acquired via natural infection,
    assuming an overall case hospitalisation ratio (CHR) of 20% and case
    fatality ratio (CFR) of 1%, this suggests an additional 18,000
    hospitalisations and 900 deaths than could be expected under the
    assumption of a seroprevalence of 10% respectfully. In at least the
    case of hospitalisation, this may require further preparation at
    hospital-level and the implementation of surge capacity
    protocols.</p>
    </boxed-text>
    <p>Where parameters are reported or inferred during an active
    outbreak, we recommend to provide information about the time into
    the outbreak since the first case was reported and epidemic phase at
    the time of the analysis, especially when inferring delay
    distributions (see section 1.5). Further contextual information is
    also relevant for a nuanced understanding of how parameter estimates
    may change throughout an outbreak, e.g., due to changes in
    containment measures, therapeutics and vaccination, or volume of
    testing. For instance, advancements in the therapeutic approach to
    critical care patients resulted in a significantly higher delay from
    onset to death for COVID-19 patients during the summer of 2020 (mean
    of 24.7 days), compared to the first wave of the pandemic (mean of
    19.6 days) (Ward and Johnsen, 2021, PLoS).</p>
    <p>Contextual information about the disease’s causative agent should
    also be reported, including pathogen name, and, where applicable,
    its type, subtype and/or strain. This information is relevant, as
    the transmissibility, pathogenicity and severity of disease, and
    their resulting epidemiological parameters often vary across strains
    of the same pathogen. For instance, the incubation period for
    Influenza type A is reportedly longer on average than that of
    Influenza type B, with a median of 1.4 and 0.6 days, respectively
    (Lessler, 2009). If the causative agent is unknown to the authors,
    either due to it being a novel pathogen, or simply because this
    information is not available, this should be explicitly stated in
    the publication. Beyond details about the causative agent, authors
    should also specify the transmission routes that have been
    considered when estimating parameters. This is particularly crucial
    for zoonotic and vector-borne diseases, where explicit clarification
    is needed on whether the estimates account for human-to-human
    transmission only, or if animal-to-human or vector-to-human
    transmission is also accounted for.</p>
    <p><italic>Guidance</italic>:</p>
    <list list-type="bullet">
      <list-item>
        <p>Provide demographic information about the population and for
        the sample that was used to estimate epidemiological
        parameters.</p>
      </list-item>
      <list-item>
        <p>Specify whether analyses were stratified by certain groups,
        e.g., by age, or conducted using data for the whole
        population.</p>
      </list-item>
      <list-item>
        <p>Indicate whether reported parameters were obtained during an
        ongoing outbreak and, if so, provide information on the epidemic
        phase and time since outbreak was first declared.</p>
      </list-item>
      <list-item>
        <p>Clearly state whether variant(s) of the pathogen of interest
        is known and, if so, report the name of the variant and how this
        was determined.</p>
      </list-item>
      <list-item>
        <p>Specify which transmission pathways of disease were
        considered, e.g., human-to-human only, or including
        animal-to-human transmission.</p>
      </list-item>
    </list>
  </sec>
  <sec id="open-science-and-reproducibility-to-enhance-reuse">
    <title>Open science and reproducibility to enhance reuse</title>
    <p>The complexities involved in estimating and reporting
    epidemiological parameters mean that it is unlikely that all
    methodological aspects and considerations can be documented in the
    paper or even supplementary material. By sharing data and code it
    enables reproducibility and auditing of the methods used. Sharing
    the code used to infer an epidemiological parameter enables others
    to see which method, as well as any other packages that were used.
    There are several platforms that easily enable code sharing, most
    common are GitHub, GitLab and BitBucket. To release the software
    used and provide a unique identifier (e.g. DOI) services like
    Zenodo, Figshare and Dyrad, this provides a single referenceable
    snapshot of the code, removing any issue if the code changes on, for
    example GitHub. Following these and other good practices for code
    sharing will help others navigate and review the code (Wilson et
    al., 2017). Openly sharing code enables others to reproduce the
    estimates and verify the estimates. They may also be able to assess
    the quality of the methods with respect to the available data and
    possible bias-adjustments that may be required when working with
    real-time outbreak data (citation needed). Sharing the analysis code
    can also resolve ambiguities in parameter reporting. If the
    parameterisation of the distribution is unclear from the text (see
    Section 1) then by checking parameter arguments in the code
    clarifies their use.</p>
    <p>Sharing the data is as important as sharing the code. By data we
    mean the input data (i.e. outbreak case data) and output data
    (i.e. parameter estimates and fitting metadata). If possible the raw
    data used to fit a model to estimate an epidemiological parameter
    should be openly available. By sharing the raw data it enables
    reproducibility of the analysis used to estimate the epidemiological
    parameters, but also allows others to apply different models to the
    data.</p>
    <p>Openly sharing epidemiological data can be restricted by personal
    identifiable information (PII) and data usage restrictions. There
    are some methods available to enable reproducibility even when the
    raw data cannot be shared. Anonymisation, if the personal
    identifiable information (PII) is not required by the method to
    infer the epidemiological parameter then this information can be
    removed, de-identified or anonymised prior to uploading the data
    (citations needed). Mock or synthetic data can be generated which
    has the same characteristics as the empirical data. This enables the
    analysis to be reproduced while removing any risk of identification
    or leaking personal information.</p>
    <p>The epidemiological parameter output should also be shared in
    full when possible. Often if the epidemiological parameter are
    distribution parameters these will be reported in the text. But the
    estimates correlation matrix, variance-covariance matrix,
    convergence metrics (e.g. …) should be shared. For Bayesian analyses
    sharing the posterior distribution is most beneficial for reuse as
    it allows researchers to calculate whichever summary metric their
    use case requires (e.g. Highest Posterior Density (HPD)
    Interval).</p>
  </sec>
  <sec id="epidemiological-parameter-use-and-disjoint-analysis-pipelines">
    <title>Epidemiological parameter use and disjoint analysis
    pipelines</title>
    <p>The aim of this paper has been to provide a set of reporting
    guidelines for epidemiological parameter, with the objective to make
    reusing them in other epidemiological analyses more reliable, with
    examples showcasing when analysis error can result from erroneous or
    ambiguous reporting. This argument is premised on the downstream
    epidemiological analysis being disjoint from the estimation of the
    epidemiological parameters, in other words the method that uses the
    parameters to estimate or infer another aspect of an outbreak does
    not estimate the parameters. An example of this is when an
    previously estimated generation time, or serial interval as a more
    commonly available replacement, is used to estimate the real-time
    reproduction number. If the data is available to jointly estimate
    the generation time or serial interval with the reproduction number,
    then this is the statistically optimal approach. However, for a
    variety of reasons, primarily model complexity of joint models
    leading to mathematical and computations simplification being
    required, the disjoint or 2-step analysis procedure is common (ref).
    Some models to offer joint estimation given sufficient data (ref).
    There have not been many studies exploring the statistical
    performance of joint versus disjoint estimation (check this sentence
    and find ref). There is another aspect to consider, whether a set of
    epidemiological parameters exists where the features of the data
    (e.g. sample size, collection procedure) make it more accurate than
    the available at hand. In this scenario even if a joint estimation
    framework is available and feasible, it might be better to choose
    estimated parameters. The contextual information of the data, such
    as demography, geography, and comorbidities of the sample, should
    also be considered in such a case as the two groups might not be
    epidemiologically equivalent. That is all to say that reporting
    guidelines are relevant due to the widespread use of disjoint
    estimation where clear, ambiguous reporting with coverage of key
    piece of statistical and contextual information are required.</p>
  </sec>
</sec>
<sec id="conclusion">
  <title>Conclusion</title>
</sec>
</body>

<back>
<ref-list>
  <title>References</title>
  <ref id="ref-cuomo-dannenburgMarburgVirusDisease2024">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Cuomo-Dannenburg</surname><given-names>Gina</given-names></name>
        <name><surname>McCain</surname><given-names>Kelly</given-names></name>
        <name><surname>McCabe</surname><given-names>Ruth</given-names></name>
        <name><surname>Unwin</surname><given-names>H Juliette T</given-names></name>
        <name><surname>Doohan</surname><given-names>Patrick</given-names></name>
        <name><surname>Nash</surname><given-names>Rebecca K</given-names></name>
        <name><surname>Hicks</surname><given-names>Joseph T</given-names></name>
        <name><surname>Charniga</surname><given-names>Kelly</given-names></name>
        <name><surname>Geismar</surname><given-names>Cyril</given-names></name>
        <name><surname>Lambert</surname><given-names>Ben</given-names></name>
        <name><surname>Nikitin</surname><given-names>Dariya</given-names></name>
        <name><surname>Skarp</surname><given-names>Janetta</given-names></name>
        <name><surname>Wardle</surname><given-names>Jack</given-names></name>
        <name><surname>Kont</surname><given-names>Mara</given-names></name>
        <name><surname>Bhatia</surname><given-names>Sangeeta</given-names></name>
        <name><surname>Imai</surname><given-names>Natsuko</given-names></name>
        <name><surname>Van Elsland</surname><given-names>Sabine</given-names></name>
        <name><surname>Cori</surname><given-names>Anne</given-names></name>
        <name><surname>Morgenstern</surname><given-names>Christian</given-names></name>
        <name><surname>Morris</surname><given-names>Aaron</given-names></name>
        <name><surname>Forna</surname><given-names>Alpha</given-names></name>
        <name><surname>Dighe</surname><given-names>Amy</given-names></name>
        <name><surname>Cori</surname><given-names>Anne</given-names></name>
        <name><surname>Hamlet</surname><given-names>Arran</given-names></name>
        <name><surname>Lambert</surname><given-names>Ben</given-names></name>
        <name><surname>Whittaker</surname><given-names>Charlie</given-names></name>
        <name><surname>Morgenstern</surname><given-names>Christian</given-names></name>
        <name><surname>Geismar</surname><given-names>Cyril</given-names></name>
        <name><surname>Nikitin</surname><given-names>Dariya</given-names></name>
        <name><surname>Jorgensen</surname><given-names>David</given-names></name>
        <name><surname>Knock</surname><given-names>Ed</given-names></name>
        <name><surname>Unwin</surname><given-names>Ettie</given-names></name>
        <name><surname>Cuomo-Dannenburg</surname><given-names>Gina</given-names></name>
        <name><surname>Thompson</surname><given-names>Hayley</given-names></name>
        <name><surname>Routledge</surname><given-names>Isobel</given-names></name>
        <name><surname>Skarp</surname><given-names>Janetta</given-names></name>
        <name><surname>Hicks</surname><given-names>Joseph</given-names></name>
        <name><surname>Fraser</surname><given-names>Keith</given-names></name>
        <name><surname>Charniga</surname><given-names>Kelly</given-names></name>
        <name><surname>McCain</surname><given-names>Kelly</given-names></name>
        <name><surname>Geidelberg</surname><given-names>Lily</given-names></name>
        <name><surname>Cattarino</surname><given-names>Lorenzo</given-names></name>
        <name><surname>Kont</surname><given-names>Mara</given-names></name>
        <name><surname>Baguelin</surname><given-names>Marc</given-names></name>
        <name><surname>Imai</surname><given-names>Natsuko</given-names></name>
        <name><surname>Moghaddas</surname><given-names>Nima</given-names></name>
        <name><surname>Doohan</surname><given-names>Patrick</given-names></name>
        <name><surname>Nash</surname><given-names>Rebecca</given-names></name>
        <name><surname>McCabe</surname><given-names>Ruth</given-names></name>
        <name><surname>Van Elsland</surname><given-names>Sabine</given-names></name>
        <name><surname>Bhatia</surname><given-names>Sangeeta</given-names></name>
        <name><surname>Radhakrishnan</surname><given-names>Sreejith</given-names></name>
        <name><surname>Cucunuba Perez</surname><given-names>Zulma</given-names></name>
        <name><surname>Wardle</surname><given-names>Jack</given-names></name>
      </person-group>
      <article-title>Marburg virus disease outbreaks, mathematical models, and disease parameters: A systematic review</article-title>
      <source>The Lancet Infectious Diseases</source>
      <year iso-8601-date="2024-05">2024</year><month>05</month>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-08-29">2024</year><month>08</month><day>29</day></date-in-citation>
      <volume>24</volume>
      <issue>5</issue>
      <issn>14733099</issn>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S1473309923005157</uri>
      <pub-id pub-id-type="doi">10.1016/S1473-3099(23)00515-7</pub-id>
      <fpage>e307</fpage>
      <lpage>e317</lpage>
    </element-citation>
  </ref>
  <ref id="ref-nashEbolaVirusDisease2024">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Nash</surname><given-names>Rebecca K</given-names></name>
        <name><surname>Bhatia</surname><given-names>Sangeeta</given-names></name>
        <name><surname>Morgenstern</surname><given-names>Christian</given-names></name>
        <name><surname>Doohan</surname><given-names>Patrick</given-names></name>
        <name><surname>Jorgensen</surname><given-names>David</given-names></name>
        <name><surname>McCain</surname><given-names>Kelly</given-names></name>
        <name><surname>McCabe</surname><given-names>Ruth</given-names></name>
        <name><surname>Nikitin</surname><given-names>Dariya</given-names></name>
        <name><surname>Forna</surname><given-names>Alpha</given-names></name>
        <name><surname>Cuomo-Dannenburg</surname><given-names>Gina</given-names></name>
        <name><surname>Hicks</surname><given-names>Joseph T</given-names></name>
        <name><surname>Sheppard</surname><given-names>Richard J</given-names></name>
        <name><surname>Naidoo</surname><given-names>Tristan</given-names></name>
        <name><surname>Van Elsland</surname><given-names>Sabine</given-names></name>
        <name><surname>Geismar</surname><given-names>Cyril</given-names></name>
        <name><surname>Rawson</surname><given-names>Thomas</given-names></name>
        <name><surname>Leuba</surname><given-names>Sequoia Iris</given-names></name>
        <name><surname>Wardle</surname><given-names>Jack</given-names></name>
        <name><surname>Routledge</surname><given-names>Isobel</given-names></name>
        <name><surname>Fraser</surname><given-names>Keith</given-names></name>
        <name><surname>Imai-Eaton</surname><given-names>Natsuko</given-names></name>
        <name><surname>Cori</surname><given-names>Anne</given-names></name>
        <name><surname>Unwin</surname><given-names>H Juliette T</given-names></name>
      </person-group>
      <article-title>Ebola virus disease mathematical models and epidemiological parameters: A systematic review</article-title>
      <source>The Lancet Infectious Diseases</source>
      <year iso-8601-date="2024-08">2024</year><month>08</month>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-08-29">2024</year><month>08</month><day>29</day></date-in-citation>
      <issn>14733099</issn>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S1473309924003748</uri>
      <pub-id pub-id-type="doi">10.1016/S1473-3099(24)00374-8</pub-id>
      <fpage>S1473309924003748</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-coriInferenceEpidemicDynamics2024">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Cori</surname><given-names>Anne</given-names></name>
        <name><surname>Kucharski</surname><given-names>Adam</given-names></name>
      </person-group>
      <article-title>Inference of epidemic dynamics in the COVID-19 era and beyond</article-title>
      <source>Epidemics</source>
      <year iso-8601-date="2024-09">2024</year><month>09</month>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-09-11">2024</year><month>09</month><day>11</day></date-in-citation>
      <volume>48</volume>
      <issn>17554365</issn>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S1755436524000458</uri>
      <pub-id pub-id-type="doi">10.1016/j.epidem.2024.100784</pub-id>
      <fpage>100784</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-polonskyOutbreakAnalyticsDeveloping2019">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Polonsky</surname><given-names>Jonathan A.</given-names></name>
        <name><surname>Baidjoe</surname><given-names>Amrish</given-names></name>
        <name><surname>Kamvar</surname><given-names>Zhian N.</given-names></name>
        <name><surname>Cori</surname><given-names>Anne</given-names></name>
        <name><surname>Durski</surname><given-names>Kara</given-names></name>
        <name><surname>Edmunds</surname><given-names>W. John</given-names></name>
        <name><surname>Eggo</surname><given-names>Rosalind M.</given-names></name>
        <name><surname>Funk</surname><given-names>Sebastian</given-names></name>
        <name><surname>Kaiser</surname><given-names>Laurent</given-names></name>
        <name><surname>Keating</surname><given-names>Patrick</given-names></name>
        <name><surname>De Waroux</surname><given-names>Olivier Le Polain</given-names></name>
        <name><surname>Marks</surname><given-names>Michael</given-names></name>
        <name><surname>Moraga</surname><given-names>Paula</given-names></name>
        <name><surname>Morgan</surname><given-names>Oliver</given-names></name>
        <name><surname>Nouvellet</surname><given-names>Pierre</given-names></name>
        <name><surname>Ratnayake</surname><given-names>Ruwan</given-names></name>
        <name><surname>Roberts</surname><given-names>Chrissy H.</given-names></name>
        <name><surname>Whitworth</surname><given-names>Jimmy</given-names></name>
        <name><surname>Jombart</surname><given-names>Thibaut</given-names></name>
      </person-group>
      <article-title>Outbreak analytics: A developing data science for informing the response to emerging pathogens</article-title>
      <source>Philosophical Transactions of the Royal Society B: Biological Sciences</source>
      <year iso-8601-date="2019-07">2019</year><month>07</month>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-09-11">2024</year><month>09</month><day>11</day></date-in-citation>
      <volume>374</volume>
      <issue>1776</issue>
      <issn>0962-8436, 1471-2970</issn>
      <uri>https://royalsocietypublishing.org/doi/10.1098/rstb.2018.0276</uri>
      <pub-id pub-id-type="doi">10.1098/rstb.2018.0276</pub-id>
      <fpage>20180276</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-vankerkhoveReviewEpidemiologicalParameters2015a">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Van Kerkhove</surname><given-names>Maria D.</given-names></name>
        <name><surname>Bento</surname><given-names>Ana I.</given-names></name>
        <name><surname>Mills</surname><given-names>Harriet L.</given-names></name>
        <name><surname>Ferguson</surname><given-names>Neil M.</given-names></name>
        <name><surname>Donnelly</surname><given-names>Christl A.</given-names></name>
      </person-group>
      <article-title>A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making</article-title>
      <source>Scientific Data</source>
      <year iso-8601-date="2015-05">2015</year><month>05</month>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-09-11">2024</year><month>09</month><day>11</day></date-in-citation>
      <volume>2</volume>
      <issue>1</issue>
      <issn>2052-4463</issn>
      <uri>https://www.nature.com/articles/sdata201519</uri>
      <pub-id pub-id-type="doi">10.1038/sdata.2015.19</pub-id>
      <fpage>150019</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-doohanLassaFeverOutbreaks2024">
    <element-citation>
      <person-group person-group-type="author">
        <name><surname>Doohan</surname><given-names>Patrick</given-names></name>
        <name><surname>Jorgensen</surname><given-names>David</given-names></name>
        <name><surname>Naidoo</surname><given-names>Tristan M.</given-names></name>
        <name><surname>McCain</surname><given-names>Kelly</given-names></name>
        <name><surname>Hicks</surname><given-names>Joseph T.</given-names></name>
        <name><surname>McCabe</surname><given-names>Ruth</given-names></name>
        <name><surname>Bhatia</surname><given-names>Sangeeta</given-names></name>
        <name><surname>Charniga</surname><given-names>Kelly</given-names></name>
        <name><surname>Cuomo-Dannenburg</surname><given-names>Gina</given-names></name>
        <name><surname>Hamlet</surname><given-names>Arran</given-names></name>
        <name><surname>Nash</surname><given-names>Rebecca K.</given-names></name>
        <name><surname>Nikitin</surname><given-names>Dariya</given-names></name>
        <name><surname>Rawson</surname><given-names>Thomas</given-names></name>
        <name><surname>Sheppard</surname><given-names>Richard J.</given-names></name>
        <name><surname>Unwin</surname><given-names>H. Juliette T.</given-names></name>
        <name><surname>Van Elsland</surname><given-names>Sabine</given-names></name>
        <name><surname>Cori</surname><given-names>Anne</given-names></name>
        <name><surname>Morgenstern</surname><given-names>Christian</given-names></name>
        <name><surname>Imai-Eaton</surname><given-names>Natsuko</given-names></name>
      </person-group>
      <article-title>Lassa fever outbreaks, mathematical models, and disease parameters: A systematic review and meta-analysis</article-title>
      <year iso-8601-date="2024-03">2024</year><month>03</month>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-09-11">2024</year><month>09</month><day>11</day></date-in-citation>
      <uri>http://medrxiv.org/lookup/doi/10.1101/2024.03.23.24304596</uri>
      <pub-id pub-id-type="doi">10.1101/2024.03.23.24304596</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-charnigaBestPracticesEstimating2024">
    <element-citation>
      <person-group person-group-type="author">
        <name><surname>Charniga</surname><given-names>Kelly</given-names></name>
        <name><surname>Park</surname><given-names>Sang Woo</given-names></name>
        <name><surname>Akhmetzhanov</surname><given-names>Andrei R</given-names></name>
        <name><surname>Cori</surname><given-names>Anne</given-names></name>
        <name><surname>Dushoff</surname><given-names>Jonathan</given-names></name>
        <name><surname>Funk</surname><given-names>Sebastian</given-names></name>
        <name><surname>Gostic</surname><given-names>Katelyn M</given-names></name>
        <name><surname>Linton</surname><given-names>Natalie M</given-names></name>
        <name><surname>Lison</surname><given-names>Adrian</given-names></name>
        <name><surname>Overton</surname><given-names>Christopher E</given-names></name>
        <name><surname>Pulliam</surname><given-names>Juliet R C</given-names></name>
        <name><surname>Ward</surname><given-names>Thomas</given-names></name>
        <name><surname>Cauchemez</surname><given-names>Simon</given-names></name>
        <name><surname>Abbott</surname><given-names>Sam</given-names></name>
      </person-group>
      <article-title>Best practices for estimating and reporting epidemiological delay distributions of infectious diseases using public health surveillance and healthcare data</article-title>
      <publisher-name>arXiv</publisher-name>
      <year iso-8601-date="2024">2024</year>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-09-11">2024</year><month>09</month><day>11</day></date-in-citation>
      <uri>https://arxiv.org/abs/2405.08841</uri>
      <pub-id pub-id-type="doi">10.48550/ARXIV.2405.08841</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-parkEstimatingEpidemiologicalDelay2024">
    <element-citation>
      <person-group person-group-type="author">
        <name><surname>Park</surname><given-names>Sang Woo</given-names></name>
        <name><surname>Akhmetzhanov</surname><given-names>Andrei R.</given-names></name>
        <name><surname>Charniga</surname><given-names>Kelly</given-names></name>
        <name><surname>Cori</surname><given-names>Anne</given-names></name>
        <name><surname>Davies</surname><given-names>Nicholas G.</given-names></name>
        <name><surname>Dushoff</surname><given-names>Jonathan</given-names></name>
        <name><surname>Funk</surname><given-names>Sebastian</given-names></name>
        <name><surname>Gostic</surname><given-names>Katie</given-names></name>
        <name><surname>Grenfell</surname><given-names>Bryan</given-names></name>
        <name><surname>Linton</surname><given-names>Natalie M.</given-names></name>
        <name><surname>Lipsitch</surname><given-names>Marc</given-names></name>
        <name><surname>Lison</surname><given-names>Adrian</given-names></name>
        <name><surname>Overton</surname><given-names>Christopher E.</given-names></name>
        <name><surname>Ward</surname><given-names>Thomas</given-names></name>
        <name><surname>Abbott</surname><given-names>Sam</given-names></name>
      </person-group>
      <article-title>Estimating epidemiological delay distributions for infectious diseases</article-title>
      <year iso-8601-date="2024-01">2024</year><month>01</month>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-09-11">2024</year><month>09</month><day>11</day></date-in-citation>
      <uri>http://medrxiv.org/lookup/doi/10.1101/2024.01.12.24301247</uri>
      <pub-id pub-id-type="doi">10.1101/2024.01.12.24301247</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-nishiuraEarlyEpidemiologicalAssessment2009">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Nishiura</surname><given-names>Hiroshi</given-names></name>
        <name><surname>Klinkenberg</surname><given-names>Don</given-names></name>
        <name><surname>Roberts</surname><given-names>Mick</given-names></name>
        <name><surname>Heesterbeek</surname><given-names>Johan A. P.</given-names></name>
      </person-group>
      <article-title>Early Epidemiological Assessment of the Virulence of Emerging Infectious Diseases: A Case Study of an Influenza Pandemic</article-title>
      <source>PLoS ONE</source>
      <person-group person-group-type="editor">
        <name><surname>Peccoud</surname><given-names>Jean</given-names></name>
      </person-group>
      <year iso-8601-date="2009-08">2009</year><month>08</month>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-09-11">2024</year><month>09</month><day>11</day></date-in-citation>
      <volume>4</volume>
      <issue>8</issue>
      <issn>1932-6203</issn>
      <uri>https://dx.plos.org/10.1371/journal.pone.0006852</uri>
      <pub-id pub-id-type="doi">10.1371/journal.pone.0006852</pub-id>
      <fpage>e6852</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-lambertSimulistSimulateDisease2024">
    <element-citation>
      <person-group person-group-type="author">
        <name><surname>Lambert</surname><given-names>Joshua W.</given-names></name>
        <name><surname>Tamayo</surname><given-names>Carmen</given-names></name>
      </person-group>
      <article-title>Simulist: Simulate Disease Outbreak Line List and Contacts Data</article-title>
      <publisher-name>Zenodo</publisher-name>
      <year iso-8601-date="2024-05">2024</year><month>05</month>
      <date-in-citation content-type="access-date"><year iso-8601-date="2024-09-11">2024</year><month>09</month><day>11</day></date-in-citation>
      <uri>https://zenodo.org/doi/10.5281/zenodo.10471458</uri>
      <pub-id pub-id-type="doi">10.5281/ZENODO.10471458</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-gupteCfrEstimateDisease2024">
    <element-citation>
      <person-group person-group-type="author">
        <name><surname>Gupte</surname><given-names>Pratik R.</given-names></name>
        <name><surname>Kucharski</surname><given-names>Adam</given-names></name>
        <name><surname>Russell</surname><given-names>Tim</given-names></name>
      </person-group>
      <article-title>Cfr: Estimate disease severity and case ascertainment</article-title>
      <year iso-8601-date="2024">2024</year>
    </element-citation>
  </ref>
</ref-list>
</back>

<sub-article article-type="notebook" id="nb-6-nb-1">
<front-stub>
</front-stub>

<body>
<sec id="cell-fig-dist-params-nb-1" specific-use="notebook-content">
<code language="r script"># Define the x values for the plot
x &lt;- seq(0, 10, length.out = 100)
shape_scale &lt;- stats::dgamma(x = x, shape = 2, scale = 2)
shape_rate &lt;- stats::dgamma(x = x, shape = 2, rate = 2)
plot(x, shape_rate, type = &quot;l&quot;, col = &quot;blue&quot;, lwd = 2, ylab = &quot;Density&quot;, 
     xlab = &quot;x&quot;, main = &quot;Gamma Distribution&quot;)
lines(x, shape_scale, col = &quot;red&quot;, lwd = 2)

meanlog_sdlog &lt;- stats::dlnorm(x = x, meanlog = 0.5, sdlog = 0.5)
mean_sd &lt;- stats::dlnorm(x = x, meanlog = 1.87, sdlog = 1)
plot(x, meanlog_sdlog, type = &quot;l&quot;, col = &quot;coral&quot;, lwd = 2, ylab = &quot;Density&quot;, 
     xlab = &quot;x&quot;, main = &quot;Lognormal Distribution&quot;)
# Add the Gamma distribution with scale = 2
lines(x, mean_sd, col = &quot;green&quot;, lwd = 2)
</code>
<fig id="fig-dist-params-1-nb-1">
  <caption><p>Differences in distributions when misinterpreting the
  estimated parameters. (a) Two gamma distributions, the blue shows a
  gamma distribution with shape (<inline-formula><alternatives>
  <tex-math><![CDATA[\alpha]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>)
  and rate (<inline-formula><alternatives>
  <tex-math><![CDATA[\beta]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>)
  of 2, the red shows a gamma distribution with shape
  (<inline-formula><alternatives>
  <tex-math><![CDATA[k]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>k</mml:mi></mml:math></alternatives></inline-formula>)
  and scale (<inline-formula><alternatives>
  <tex-math><![CDATA[\theta]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>θ</mml:mi></mml:math></alternatives></inline-formula>)
  of 2. The rate is the reciprocal of the scale
  (<inline-formula><alternatives>
  <tex-math><![CDATA[\beta]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>
  = 1/<inline-formula><alternatives>
  <tex-math><![CDATA[\theta]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>θ</mml:mi></mml:math></alternatives></inline-formula>),
  but it is clear from the left hand plot that misinterpreting the
  parameter leads to a vastly different distribution density. (b) Two
  lognormal distributions, the orange shows the density of a lognormal
  distribution with meanlog (<inline-formula><alternatives>
  <tex-math><![CDATA[\mu]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>)
  and sdlog (<inline-formula><alternatives>
  <tex-math><![CDATA[\sigma]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>σ</mml:mi></mml:math></alternatives></inline-formula>)
  of 0.5, and the green with the meanlog and sdlog of 1.87 and 1.00,
  respectively (these values are the conversion from meanlog and sdlog
  into mean and standard deviation). Again showing how misinterpreting
  the parameters can lead to differences in epidemiological
  parameters.</p></caption>
  <graphic mimetype="image" mime-subtype="png" xlink:href="dist_params_files/figure-jats/fig-dist-params-1.png" />
</fig>
<fig id="fig-dist-params-2-nb-1">
  <caption><p>Differences in distributions when misinterpreting the
  estimated parameters. (a) Two gamma distributions, the blue shows a
  gamma distribution with shape (<inline-formula><alternatives>
  <tex-math><![CDATA[\alpha]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>)
  and rate (<inline-formula><alternatives>
  <tex-math><![CDATA[\beta]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>)
  of 2, the red shows a gamma distribution with shape
  (<inline-formula><alternatives>
  <tex-math><![CDATA[k]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>k</mml:mi></mml:math></alternatives></inline-formula>)
  and scale (<inline-formula><alternatives>
  <tex-math><![CDATA[\theta]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>θ</mml:mi></mml:math></alternatives></inline-formula>)
  of 2. The rate is the reciprocal of the scale
  (<inline-formula><alternatives>
  <tex-math><![CDATA[\beta]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>
  = 1/<inline-formula><alternatives>
  <tex-math><![CDATA[\theta]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>θ</mml:mi></mml:math></alternatives></inline-formula>),
  but it is clear from the left hand plot that misinterpreting the
  parameter leads to a vastly different distribution density. (b) Two
  lognormal distributions, the orange shows the density of a lognormal
  distribution with meanlog (<inline-formula><alternatives>
  <tex-math><![CDATA[\mu]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>)
  and sdlog (<inline-formula><alternatives>
  <tex-math><![CDATA[\sigma]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>σ</mml:mi></mml:math></alternatives></inline-formula>)
  of 0.5, and the green with the meanlog and sdlog of 1.87 and 1.00,
  respectively (these values are the conversion from meanlog and sdlog
  into mean and standard deviation). Again showing how misinterpreting
  the parameters can lead to differences in epidemiological
  parameters.</p></caption>
  <graphic mimetype="image" mime-subtype="png" xlink:href="dist_params_files/figure-jats/fig-dist-params-2.png" />
</fig>
</sec>
</body>



<back>
</back>


</sub-article>
<sub-article article-type="notebook" id="nb-10-nb-2">
<front-stub>
</front-stub>

<body>
<p>Issue: A measure of uncertainty is provided, but it is not clear
whether this uncertainty is due to sample variability, or is an
uncertainty around the estimator.</p>
<p>Implication: Erronoeus attribution of uncertainty to sample
variability or vice versa can bias the downstream analysis. This is
particularly true when the underlying data are not shared.</p>
<p>Illustration: We illustrate this issue using simulated data from a
gamma distribution D. We first simulate some data, get the observed mean
and sd, and the uncertainty around these estimates. We then compare the
observed data with that simulated with the erroneous interpretation of
the uncertainty.</p>
<sec specific-use="notebook-content">
<code language="r script">library(epitrix)
library(ggplot2)
library(purrr)

### Setting up the data simulation
set.seed(1)
mean_delay &lt;- 5
sd_delay &lt;- 3
params_gamma &lt;- gamma_mucv2shapescale(mu = mean_delay, cv = sd_delay / mean_delay)
sample_size &lt;- list(small = 20, large = 100)
samples &lt;- map(
  sample_size, ~rgamma(.x, shape = params_gamma$shape, scale = params_gamma$scale)
)

obs_mu &lt;- map_dbl(samples, mean)
obs_sd &lt;- map_dbl(samples, sd)

## Bootstrap to find the distribution of the mean and sd
n_boot &lt;- 100
boot_samples &lt;- map(samples, ~ replicate(n_boot, sample(.x, replace = TRUE)))
## Each element of this list is a matrix with 1000 rows and 10000 columns
## That is, each row is a bootstrap sample of the original data
boot_means &lt;- map(boot_samples, colMeans)
boot_sds &lt;- map(boot_samples, ~ apply(.x, 2, sd))
## Precision of estimates; 
precision_mu &lt;- map(boot_means, sd)
precision_sd &lt;- map(boot_sds, sd)

## Treat precision_mu as sample SD; assume large sample size in downstream analysis
## probably be large.
wrong_sample &lt;- map2(
 obs_mu, precision_mu, function(x, y) {
    params &lt;- gamma_mucv2shapescale(mu = x, cv = y / x)
    rgamma(1000, shape = params$shape, scale = params$scale)
 }
)
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script">ggplot() + 
  geom_density(aes(x = samples$small), fill = &quot;blue&quot;, alpha = 0.5, col = NA) +
geom_density(aes(x = wrong_sample$small), fill = &quot;red&quot;, alpha = 0.5, col = NA) +
  theme_bw()
</code>
<graphic mimetype="image" mime-subtype="png" xlink:href="sample_variability_vs_uncertainty_files/figure-jats/unnamed-chunk-2-1.png" />
</sec>
</body>



<back>
</back>


</sub-article>
<sub-article article-type="notebook" id="nb-14-nb-3">
<front-stub>
</front-stub>

<body>
<p><bold>Example use case: estimating the upper quantile of the
incubation period distribution</bold></p>
<sec specific-use="notebook-content">
<code language="r script">library(tidyverse)
</code>
<boxed-text>
  <preformat>── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
✔ dplyr     1.1.4     ✔ readr     2.1.5
✔ forcats   1.0.0     ✔ stringr   1.5.1
✔ ggplot2   3.5.1     ✔ tibble    3.2.1
✔ lubridate 1.9.3     ✔ tidyr     1.3.1
✔ purrr     1.0.2     
── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
✖ dplyr::filter() masks stats::filter()
✖ dplyr::lag()    masks stats::lag()
ℹ Use the conflicted package (&lt;http://conflicted.r-lib.org/&gt;) to force all conflicts to become errors</preformat>
</boxed-text>
<code language="r script">library(matrixStats)
</code>
<boxed-text>
  <preformat>
Attaching package: 'matrixStats'

The following object is masked from 'package:dplyr':

    count</preformat>
</boxed-text>
<code language="r script">library(epiparameter)
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># notes from spreadsheet
# characterise upper quantile e.g. 95% of incubation period to estimate the duration of contact tracing follow up
# Can get a central estimate from the central estimate of mean and central estimate of sd but cannot get uncertainty around that

## inspiration: https://www.nejm.org/doi/suppl/10.1056/NEJMc1414992/suppl_file/nejmc1414992_appendix.pdf

## Table S2 (Guinea)
## given a mean and SD with uncertainty around it
## overall: mean 12.6 (9.1 - 17.1) SD 13.1 (9.6 - 19.6)

mean_c &lt;- 12.6
sd_c &lt;- 13.1

# bounds which we'll use in our simulation to generate the &quot;true&quot; distribution
mean_l &lt;- 9.1
mean_u &lt;- 17.1
sd_l &lt;- 9.6
sd_u &lt;- 19.6
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script">## generate a full set of samples - taken as the &quot;true&quot; distribution which the analysis is based on

n_samples &lt;- 1000
n_iter &lt;- 100

samples &lt;- matrix(NA,nrow=n_samples,ncol=n_iter)
for(i in 1:n_iter){
  
  ## sample a mean &amp; SD
  mean_iter &lt;- rnorm(n=1,mean=mean_c,sd=(mean_u-mean_l)/3.92)
  sd_iter &lt;- rnorm(n=1,mean=sd_c,sd=(sd_u-sd_l)/3.92)
  
  # generate parameters accordingly
  param_iter &lt;- convert_summary_stats_to_params(x=&quot;gamma&quot;,
                                                mean=mean_iter,sd=sd_iter)

  samples[,i] &lt;- rgamma(n=n_samples, 
                        shape = param_iter$shape, scale = param_iter$scale)
}

## for plotting
samples_longer &lt;- pivot_longer(data.frame(samples),cols=paste0(&quot;X&quot;,seq(1:n_iter)))
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script">## now we don't have the full set of samples and we try to generate the 95% quantile 

## shape (alpha)
param1 &lt;- convert_summary_stats_to_params(x=&quot;gamma&quot;,mean=mean_c,sd=sd_c)

# estimate 95% quantile
qgamma(p=0.95,shape = param1$shape, scale = param1$scale) ## 38.08
</code>
<boxed-text>
  <preformat>[1] 38.80294</preformat>
</boxed-text>
<code language="r script">## alternative method: sample from gamma distribution and take upper quantile

# sample from gamma distribution
samples1 &lt;- rgamma(n=10000, shape = param1$shape, scale = param1$scale)

# check that things behaving as we would expect
mean(samples1)
</code>
<boxed-text>
  <preformat>[1] 12.71844</preformat>
</boxed-text>
<code language="r script">quantile(samples1,0.95) # 38.54
</code>
<boxed-text>
  <preformat>     95% 
38.84351 </preformat>
</boxed-text>
<code language="r script">## essentially both are recovering the central estimate well but not anything else
</code>
</sec>
<p>The incubation period, defined as the time between infection and the
development of symptoms, is an important epidemiological quantity for
establishing guidance on the duration of contact tracing of identified
cases, as well as the duration of isolation or quarantine for
subsequently identified contacts. It is critical that the duration of
isolation mitigates the risk of onward transmission, but does not extend
any longer than necessary due to the costs, both financial and social,
associated with isolation.
The incubation period is most typically presented as a probability
distribution, but is often summarised by a mean and estimate of the
variability (most commonly standard deviation), rather than the full
distribution.
Consider the following example. During a novel Ebola outbreak, the
incubation period is estimated using a gamma distribution on just a
small number of observations (due to the lack of testing and contact
tracing). MCMC methods are used to obtain 100 realisations of a gamma
distribution:</p>
<sec specific-use="notebook-content">
<code language="r script"># ggplot(samples_longer,
#        aes(x=value,group=name))+
#   geom_density(lwd=0.01,col=&quot;grey&quot;)+
#   theme_bw()+
#   labs(x=&quot;Day&quot;,y=&quot;Density&quot;,col=&quot;&quot;)+
#   xlim(c(0,100))

q95 &lt;- mean(colQuantiles(samples,probs=0.95)) 
l95 &lt;- quantile(colQuantiles(samples,probs=0.95),0.025)
u95 &lt;- quantile(colQuantiles(samples,probs=0.95),0.975)

ggplot(samples_longer,
       aes(x=value,group=name))+
  stat_ecdf(geom = &quot;step&quot;,col=&quot;grey&quot;)+
  geom_hline(aes(yintercept=0.95),linetype=&quot;dashed&quot;)+ 
  geom_point(aes(x=q95,y=0.95),col=&quot;blue&quot;,size=3)+
  geom_linerange(aes(y=0.95,xmin=l95,xmax=u95),col=&quot;blue&quot;,lwd=1)+
  theme_bw()+
  labs(x=&quot;Day&quot;,y=&quot;Density&quot;,col=&quot;&quot;)+
  xlim(c(0,150))+
  ylim(c(0,1))
</code>
<boxed-text>
  <preformat>Warning: Removed 4 rows containing non-finite outside the scale range
(`stat_ecdf()`).</preformat>
</boxed-text>
<graphic mimetype="image" mime-subtype="png" xlink:href="incubation_period_files/figure-jats/unnamed-chunk-5-1.png" />
</sec>
<p>This analysis has been repeated several times for this paper,
corresponding to different locations and time periods. For sake of space
and simplicity, the results per fit are presented in the typical
fashion, as noted above:
Mean: 12.4 (95% CI 8.45 - 16.92)
SD: 13.15 (95% CI 9.42 - 17.45)
However, this omits critical information about the upper 95% quantile of
the distribution, which from the figure, is highly variable across
realisations. Specifically, this is estimated as:
95% quantile: 38.7 (95% CI 28.8 - 48.8)
which has substantial uncertainty.
In a future outbreak of a viral hemorrhagic fever, the public health
authority in the affected country looks to the previous analysis to
guide their quarantine policy. Using only the provided information (the
mean and SD), it is possible to use method of moments for the gamma
distribution to obtain estimates of the shape and scale parameters (0.93
and 13.62, respectively). Parameterising a gamma distribution according
to these parameters corresponds to a 95% quantile of 39 days. This
recovers the central estimate above well. However, it is not possible to
obtain any uncertainty around this estimate without the authors having
provided the full set of samples used to generate these estimates. This
may provide a false sense of certainty on which the quarantine policy is
based, whereas there may be an argument to either extend or reduce this
based on the considerable uncertainty estimated above.</p>
</body>



<back>
</back>


</sub-article>
<sub-article article-type="notebook" id="nb-18-nb-4">
<front-stub>
</front-stub>

<body>
<p><bold>Use case: Ambiguous reporting of onset-to-death delay
distribution and erroneous CFR estimates</bold></p>
<p>In a scenario in which the case fatality risk (CFR) needs to be
calculated for an ongoing, growing disease outbreak an onset-to-death
delay distribution is required to calculate an unbiased CFR estimate,
due to some individuals being infected but theiry outcome (i.e recovery
or death) is unknown @nishiuraEarlyEpidemiologicalAssessment2009.</p>
<p>A line list of the current outbreak is available, but no estiates of
the onset-to-death delay are available for this outbreak and there is
not enough case data to reliably estimate it from the line list.
Therefore a previously inferred onset-to-death distribution is searched
and extracted from the literature for the same pathogen from a past
outbreak.</p>
<p>The paper reporting the onset-to-death states:</p>
<disp-quote>
  <p>“… the average duration between the time when symptoms first
  appeared and death of the patients was estimated. The mean
  onset-to-death delay was of 14.5 days, with a standard deviation of
  6.7.”</p>
</disp-quote>
<p>The ambiguous reporting of the esimates means the onset-to-death
delay can be (mis)interpreted in several ways. The paper is reporting
the summary statistics mean and standard deviation for a lognormal
distribution they fitted to the data. The estimates could be
misinterpreted as meanlog and sdlog do the lognormal distribution, or
could be misinterpreted as the summary statistics of the raw data
(i.e. sample statistics). The CFR calculation for an unbiased estimate
requires a parametric probability density/mass function. Therefore,
given the ambiguity we demonstrate the correct interpretation and three
misinterpretations of the reported onset-to-death and show how the CFR
varies as a result. We use the {simulist} and {cfr} R packages to
simulate line list data and calculate the CFR, respectively
@lambertSimulistSimulateDisease2024 and
@gupteCfrEstimateDisease2024.</p>
<sec specific-use="notebook-content">
<code language="r script"># Use case for reporting guidance paper #2- Mean of the sample reported
# ambiguously so it's confused with the mean of the lognormal distribution
library(simulist)
library(epiparameter)
library(tidyverse)
</code>
<boxed-text>
  <preformat>── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
✔ dplyr     1.1.4     ✔ readr     2.1.5
✔ forcats   1.0.0     ✔ stringr   1.5.1
✔ ggplot2   3.5.1     ✔ tibble    3.2.1
✔ lubridate 1.9.3     ✔ tidyr     1.3.1
✔ purrr     1.0.2     
── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
✖ dplyr::filter() masks stats::filter()
✖ dplyr::lag()    masks stats::lag()
ℹ Use the conflicted package (&lt;http://conflicted.r-lib.org/&gt;) to force all conflicts to become errors</preformat>
</boxed-text>
<code language="r script">library(incidence2)
</code>
<boxed-text>
  <preformat>Loading required package: grates

Attaching package: 'grates'

The following objects are masked from 'package:lubridate':

    epiweek, isoweek, year</preformat>
</boxed-text>
<code language="r script">library(cfr)
library(tidyr)
library(dplyr)
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># Step 1: Simulating data for the use case with o-d lognormal and CFR of 30%
contact_distribution &lt;- epiparameter(
  disease = &quot;COVID-19&quot;,
  epi_dist = &quot;contact distribution&quot;,
  prob_distribution = &quot;pois&quot;,
  prob_distribution_params = c(mean = 3)
)
</code>
<boxed-text>
  <preformat>Citation cannot be created as author, year, journal or title is missing</preformat>
</boxed-text>
<code language="r script">ip_COVID &lt;- epiparameter(
  disease = &quot;COVID-19&quot;,
  epi_dist = &quot;infectious period&quot;,
  prob_distribution = &quot;gamma&quot;,
  prob_distribution_params = c(shape = 3, scale = 3)
)
</code>
<boxed-text>
  <preformat>Citation cannot be created as author, year, journal or title is missing</preformat>
</boxed-text>
<code language="r script">o_d_COVID &lt;- epiparameter_db(
  disease = &quot;covid-19&quot;,
  epi_dist = &quot;onset to death&quot;,
  single_epiparameter = TRUE
)
</code>
<boxed-text>
  <preformat>Using Linton N, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov A, Jung S, Yuan
B, Kinoshita R, Nishiura H (2020). &quot;Incubation Period and Other
Epidemiological Characteristics of 2019 Novel Coronavirus Infections
with Right Truncation: A Statistical Analysis of Publicly Available
Case Data.&quot; _Journal of Clinical Medicine_. doi:10.3390/jcm9020538
&lt;https://doi.org/10.3390/jcm9020538&gt;.. 
To retrieve the citation use the 'get_citation' function</preformat>
</boxed-text>
<code language="r script">set.seed(123)
linelist_covid &lt;- sim_linelist(
  contact_distribution = contact_distribution, 
  infectious_period = ip_COVID,
  prob_infect = 0.7,
  onset_to_hosp = NULL,
  hosp_risk = NULL,
  non_hosp_death_risk = 0.3,
  onset_to_death = o_d_COVID,
  outbreak_size = c(1000, 2000)
)
</code>
<boxed-text>
  <preformat>Warning: Number of cases exceeds maximum outbreak size. 
Returning data early with 2272 cases and 3246 total contacts (including cases).</preformat>
</boxed-text>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># STEP 2: Aggregation
linelist_covid &lt;- linelist_covid %&gt;%
  tidyr::pivot_wider(
    names_from = outcome,
    values_from = date_outcome
  ) %&gt;%
  dplyr::rename(
    date_death = died,
    date_recovery = recovered
  )

incidence_COVID &lt;- incidence2::incidence(
  linelist_covid, 
  date_index = c(&quot;date_onset&quot;, &quot;date_death&quot;), 
  interval = 1L
)

incidence_COVID$date_index &lt;- as.Date(incidence_COVID$date_index)
covid_inc_cfr &lt;- cfr::prepare_data(
  incidence_COVID, 
  cases_variable = &quot;date_onset&quot;, 
  deaths_variable = &quot;date_death&quot;
)
</code>
<boxed-text>
  <preformat>NAs in cases and deaths are being replaced with 0s: Set `fill_NA = FALSE` to prevent this.</preformat>
</boxed-text>
<code language="r script">ggplot2::ggplot(
  data = covid_inc_cfr, 
  mapping = ggplot2::aes(x = date)
) + 
  ggplot2::geom_point(
    mapping = ggplot2::aes(y = cases), 
    colour = &quot;blue&quot;
  ) +
  ggplot2::geom_point(
    mapping = ggplot2::aes(y = deaths), 
    colour = &quot;red&quot;) + 
  ggplot2::theme_bw() + 
  ggplot2::scale_x_date(date_breaks = &quot;7 days&quot;)
</code>
<graphic mimetype="image" mime-subtype="png" xlink:href="cfr_dist_params_files/figure-jats/unnamed-chunk-3-1.png" />
</sec>
<sec specific-use="notebook-content">
<code language="r script"># STEP 3: Truncating data
# Real-time point at 2023-01-09

real_time &lt;- &quot;2023-01-27&quot;
incidence_rt_covid &lt;- covid_inc_cfr[covid_inc_cfr$date &lt;= real_time,]
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># STEP 4: Converting parameters
true_dist_params &lt;- get_parameters(o_d_COVID)
true_dist_summary_stats &lt;- convert_params_to_summary_stats(&quot;lnorm&quot;, meanlog = true_dist_params[[&quot;meanlog&quot;]], sdlog = true_dist_params[[&quot;sdlog&quot;]])
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># STEP 5: Problem statement

# We want to estimate the delay-adjusted CFR on our own outbreak data, and for this
# we look at the available literature where we find a publication that reports the delay
# from disease onset to death as follows:
# &quot;... the average duration between the time when symptoms first appeared and
# death of the patients was estimated. The mean onset-death delay was of 14.5 days,
# with a standard deviation of 6.7&quot;


# 14.5 and 6.7 are really distribution summary stats

# TRUE CFR

true_cfr &lt;- cfr::cfr_static(
  incidence_rt_covid, 
  delay_density = function(x) {
    dlnorm(
      x, 
      meanlog = true_dist_params[[&quot;meanlog&quot;]], 
      sdlog = true_dist_params[[&quot;sdlog&quot;]]
    )
  }
)

# a) We think they are meanlog and sdlog
crf_assumed_params &lt;- cfr::cfr_static(
  incidence_rt_covid, 
  delay_density = function(x) {
    dlnorm(
      x, 
      meanlog = true_dist_summary_stats[[&quot;mean&quot;]], 
      sdlog = true_dist_summary_stats[[&quot;sd&quot;]]
    )
  }
)
</code>
<boxed-text>
  <preformat>Total deaths = 22 and expected outcomes = 14 so setting expected outcomes = NA. If we were to assume
        total deaths = expected outcomes, it would produce an estimate of 1.</preformat>
</boxed-text>
<code language="r script"># b) We think they are sample statistics
# b.1) Lognormal to randomly generate sample and lognormal fitted distribution
lnorm_sample &lt;- rlnorm(
  n = 500, 
  meanlog = true_dist_params[[&quot;meanlog&quot;]], 
  sdlog = true_dist_params[[&quot;sdlog&quot;]]
)

lnorm_fit &lt;- fitdistrplus::fitdist(data = lnorm_sample, distr = &quot;lnorm&quot;)

cfr_sample_lnorm &lt;- cfr::cfr_static(
  incidence_rt_covid, 
  delay_density = function(x) {
    dlnorm(
      x, 
      meanlog = lnorm_fit$estimate[[&quot;meanlog&quot;]], 
      sdlog = lnorm_fit$estimate[[&quot;sdlog&quot;]]
    )
  }
)

# b.2) Gamma and gamma
gamma_parameters &lt;- convert_summary_stats_to_params(
  &quot;gamma&quot;,
  mean = true_dist_summary_stats[[&quot;mean&quot;]], 
  sd = true_dist_summary_stats[[&quot;sd&quot;]]
)

gamma_sample &lt;- rgamma(
  n = 500, 
  shape = gamma_parameters$shape, 
  scale = gamma_parameters$scale
)

gamma_fit &lt;- fitdistrplus::fitdist(data = gamma_sample, distr = &quot;gamma&quot;)

cfr_sample_gamma &lt;- cfr::cfr_static(
  incidence_rt_covid, 
  delay_density = function(x) {
    dgamma(
      x, 
      shape = gamma_fit$estimate[[&quot;shape&quot;]], 
      rate = gamma_fit$estimate[[&quot;rate&quot;]]
    )
  }
)
</code>
</sec>
<p>The correct interpretation can analytically convert the mean and
standard deviation to the lognormal distribution parameters
(<inline-formula><alternatives>
<tex-math><![CDATA[\mu]]></tex-math>
<mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>
= 2.86, <inline-formula><alternatives>
<tex-math><![CDATA[\sigma]]></tex-math>
<mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>σ</mml:mi></mml:math></alternatives></inline-formula>
= 0.53) and parameterise the onset-to-death, resulting in a CFR of
0.3042, or 30.42%. Misinterpreting the estimates to be the lognormal
parameters results in an overestimated CFR of NA. Assuming that the
reported estimates are sample summary statistics, the distribution can
be assumed, here we test the assumption that it is a lognormal (correct
assumption) and a gamma distribution (incorrect assumption). The assumed
parametric distribution form can be used to simulate a sample and the
same distribution can be fit to that sample to estimate the parameters.
In the case of assuming a lognormal distribution the CFR is estimated as
0.2681, whereas assuming a gamma distribution results in a CFR of
0.2426. The estimated CFR is biased in both cases but more so when the
distribution is assumed incorrectly.</p>
</body>



<back>
</back>


</sub-article>
<sub-article article-type="notebook" id="nb-22-nb-5">
<front-stub>
</front-stub>

<body>
<sec specific-use="notebook-content">
<code language="r script"># load finalsize
library(finalsize)
library(socialmixr)
</code>
<boxed-text>
  <preformat>
Attaching package: 'socialmixr'</preformat>
</boxed-text>
<boxed-text>
  <preformat>The following object is masked from 'package:utils':

    cite</preformat>
</boxed-text>
<code language="r script">library(ggplot2)
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># get UK polymod data from socialmixr
polymod &lt;- socialmixr::polymod
contact_data &lt;- socialmixr::contact_matrix(
  polymod,
  countries = &quot;United Kingdom&quot;,
  age.limits = c(0, 5, 18, 40, 65),
  symmetric = TRUE
)
</code>
<boxed-text>
  <preformat>Using POLYMOD social contact data. To cite this in a publication, use the 'get_citation()' function</preformat>
</boxed-text>
<boxed-text>
  <preformat>Removing participants that have contacts without age information. To change this behaviour, set the 'missing.contact.age' option</preformat>
</boxed-text>
<boxed-text>
  <preformat>Warning in pop_age(survey.pop, part.age.group.present, ...): Not all age groups represented in population data (5-year age band).
  Linearly estimating age group sizes from the 5-year bands.</preformat>
</boxed-text>
<code language="r script"># get the contact matrix and demography data
contact_matrix &lt;- t(contact_data$matrix)
demography_vector &lt;- contact_data$demography$population

# scale the contact matrix so the largest eigenvalue is 1.0
contact_matrix &lt;- contact_matrix / max(Re(eigen(contact_matrix)$values))

# divide each row of the contact matrix by the corresponding demography
contact_matrix &lt;- contact_matrix / demography_vector

n_demo_grps &lt;- length(demography_vector)
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># mean R0 is 1.5
r0_mean &lt;- 1.5
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># susceptibility is uniform
susc_uniform &lt;- matrix(
  data = 1,
  nrow = n_demo_grps,
  ncol = 1L
)

# p_susceptibility is uniform
p_susc_uniform &lt;- susc_uniform
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># create an R0 samples vector
r0_samples &lt;- rnorm(n = 1000, mean = r0_mean, sd = 0.1)
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># run final size on each sample with the same data
final_size_data &lt;- Map(
  r0_samples, seq_along(r0_samples),
  f = function(r0, i) {
    # the i-th final size estimate
    fs &lt;- final_size(
      r0 = r0,
      contact_matrix = contact_matrix,
      demography_vector = demography_vector,
      susceptibility = susc_uniform,
      p_susceptibility = p_susc_uniform
    )

    fs$replicate &lt;- i
    fs$r0_estimate &lt;- r0
    fs
  }
)

# combine data
final_size_data &lt;- Reduce(x = final_size_data, f = rbind)

# order age groups
final_size_data$demo_grp &lt;- factor(
  final_size_data$demo_grp,
  levels = contact_data$demography$age.group
)

# examine some replicates in the data
head(final_size_data, 15)
</code>
<boxed-text>
  <preformat>   demo_grp   susc_grp susceptibility p_infected replicate r0_estimate
1     [0,5) susc_grp_1              1  0.3962990         1    1.468050
2    [5,18) susc_grp_1              1  0.6677518         1    1.468050
3   [18,40) susc_grp_1              1  0.5152764         1    1.468050
4   [40,65) susc_grp_1              1  0.4424402         1    1.468050
5       65+ susc_grp_1              1  0.2877473         1    1.468050
6     [0,5) susc_grp_1              1  0.3730318         2    1.432011
7    [5,18) susc_grp_1              1  0.6417992         2    1.432011
8   [18,40) susc_grp_1              1  0.4881811         2    1.432011
9   [40,65) susc_grp_1              1  0.4170065         2    1.432011
10      65+ susc_grp_1              1  0.2686034         2    1.432011
11    [0,5) susc_grp_1              1  0.4131099         3    1.495137
12   [5,18) susc_grp_1              1  0.6857633         3    1.495137
13  [18,40) susc_grp_1              1  0.5345683         3    1.495137
14  [40,65) susc_grp_1              1  0.4607371         3    1.495137
15      65+ susc_grp_1              1  0.3017762         3    1.495137</preformat>
</boxed-text>
</sec>
</body>



<back>
</back>


</sub-article>
<sub-article article-type="notebook" id="nb-26-nb-6">
<front-stub>
</front-stub>

<body>
<p><bold>Example use case: the importance of clear reporting of
seroprevalence estimates</bold></p>
<sec specific-use="notebook-content">
<code language="r script">knitr::opts_chunk$set(echo = TRUE)
library(tidyverse)
</code>
<boxed-text>
  <preformat>── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
✔ dplyr     1.1.4     ✔ readr     2.1.5
✔ forcats   1.0.0     ✔ stringr   1.5.1
✔ ggplot2   3.5.1     ✔ tibble    3.2.1
✔ lubridate 1.9.3     ✔ tidyr     1.3.1
✔ purrr     1.0.2     
── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
✖ dplyr::filter() masks stats::filter()
✖ dplyr::lag()    masks stats::lag()
ℹ Use the conflicted package (&lt;http://conflicted.r-lib.org/&gt;) to force all conflicts to become errors</preformat>
</boxed-text>
<code language="r script">library(matrixStats)
</code>
<boxed-text>
  <preformat>
Attaching package: 'matrixStats'

The following object is masked from 'package:dplyr':

    count</preformat>
</boxed-text>
<code language="r script">library(binom)
options(scipen=999)
</code>
</sec>
<sec specific-use="notebook-content">
<code language="r script"># essentially we have a scenario in which the neutralisation tests are not reported with the correct denominator and it implies a higher seroprevalence than it actually is, which in turn could suggest a smaller susceptible population 

# set up some numbers
total_tests &lt;- 5000
positive_elisa &lt;- 250
positive_neutralisation &lt;- 50

## could then also talk about if this was just HCWs but that seems patronising?
</code>
</sec>
<p>Estimates of seroprevalence provide critical insights into the level
of susceptibility within a population, in turn informing the
implementation of control measures, including vaccinations (e.g. through
the critical fraction requiring vaccination to control spread).
A novel coronavirus has been identified and is spreading throughout the
population. A rapid seroprevalence study is undertaken to understand
levels of immunity of the population. Initially, 5,000 tests are carried
out via enzyme-linked immunoabsorbsent assay (ELISA), of which 250 are
positive. This corresponds to a seroprevalence estimate of 5% (95% exact
binomial confidence intervals 4.4% - 5.6%).
However, it is known that ELISA assays can be prone to cross-reactivity
with other coronaviruses, which are also in circulation in this
population. Therefore, it is decided to undertake neutralisation tests,
which are typically more sensitive, to provide further confidence in the
level of population-immunity. Due to a limited budget, only 500 tests
can be re-tested with a neutralisation assay, and so all of the 250
positive tests and 250 of the 4,750 negatives are selected randomly for
further testing.
Of the 500 samples sent for further testing, only 50 return as positive.
For the neutralisation tests, in respect of the ELISA tests, this
corresponds to a seroprevalence estimate of 10% (95% exact binomial
confidence intervals 7.5% - 13%), which is notably higher than the
seroprevalence obtained under ELISA only.
However, discounting the results of the 4,500 tests incorrectly inflates
estimated seroprevalence, implying a higher level of immunity in the
population than that which is indicated by this study as a whole.
Looking at the positive neutralisation tests out of the total tests
(ELISA and neutralisation), seroprevalence is estimated as 1% (95% exact
binomial confidence intervals 0.7% - 1.3%), again subtantially lower
than suggested when using the neutralisation test denominator only.
</p>
<sec specific-use="notebook-content">
<code language="r script">#look at why this matters

# total population size
pop_size &lt;- 1000000
# R0
r0 &lt;- 4
# herd immunity threshold
hit &lt;- 1-1/r0
# sero diff
sero_diff &lt;- binom.confint(x = positive_neutralisation,n = 2*positive_elisa,method=&quot;exact&quot;)$mean - binom.confint(x = positive_neutralisation,n = total_tests,method=&quot;exact&quot;)$mean 
# CFR
cfr &lt;- 0.01
# case hospitalisation ratio
chr &lt;- 0.2
</code>
</sec>
<p>Using the incorrect denominator could have important consequences for
future planning and control strategies. Consider a population of
1,000,000 people. The basic reproduction number of this novel
coronavirus is estimated at around 4, implying a herd immunity threshold
(HIT) of 75%.
If it is (incorrectly) assumed that seroprevalence is 10%, this implies
that 660,000 members of the population require immunity before herd
immunity is reached. However, it is actually 740,000 members of the
population requiring immunity to reach this threshold (an additional
90,000 people) under the correctly specified seroprevalence estimate of
1%.
If immunity were to be required through vaccination, then an additional
90,000 vaccines would be required. In the absence of a vaccine, e.g. if
immunity were to be acquired via natural infection, assuming an overall
case hospitalisation ratio (CHR) of 20% and case fatality ratio (CFR) of
1%, this suggests an additional 18,000 hospitalisations and 900 deaths
than could be expected under the assumption of a seroprevalence of 10%
respectfully. In at least the case of hospitalisation, this may require
further preparation at hospital-level and the implementation of surge
capacity protocols.</p>
<sec specific-use="notebook-content">
<code language="r script">### team, do we want a plot of something related to this?
</code>
</sec>
</body>



<back>
</back>


</sub-article>
<sub-article article-type="notebook" id="nb-2-nb-7">
<front-stub>
</front-stub>

<body>
<sec id="mit-license-nb-7">
  <title>MIT License</title>
  <p>Copyright (c) 2024 epiparameterReportingGuidance authors</p>
  <p>Permission is hereby granted, free of charge, to any person
  obtaining a copy of this software and associated documentation files
  (the “Software”), to deal in the Software without restriction,
  including without limitation the rights to use, copy, modify, merge,
  publish, distribute, sublicense, and/or sell copies of the Software,
  and to permit persons to whom the Software is furnished to do so,
  subject to the following conditions:</p>
  <p>The above copyright notice and this permission notice shall be
  included in all copies or substantial portions of the Software.</p>
  <p>THE SOFTWARE IS PROVIDED “AS IS”, WITHOUT WARRANTY OF ANY KIND,
  EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF
  MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.
  IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY
  CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT,
  TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE
  SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.</p>
</sec>
</body>



<back>
</back>


</sub-article>
<sub-article article-type="notebook" id="nb-30-nb-8">
<front-stub>
</front-stub>

<body>
<p>Epidemiological parameters are a necessity in understanding the
spread of infectious disease; from the rate of transmission, to
severity, to serology, these parameters underline our ability to
quantify and respond to disease outbreaks. The estimation of
epidemiological parameters has a long history in epidemiology and the
models and methods applied have become more complex; and with this
complexity comes the numerous ways parameters can be reported in the
literature. Here we provide guidance on how to clearly communicate
estimated epidemiological parameters, to maximise their secondary use
and minimise possible human errors that come with extracting parameters
from the literature and applying them in their own epidemiological
analysis. Our aim is for future work that reports epidemiological
parameters to be consistent, reproducible and comparable.</p>
</body>



<back>
</back>


</sub-article>

</article>